Therapeutic relevance of pharmacogenetic factors in cardiovascular medicine

被引：22

作者：

Nakagawa, K ^{[1
]}

Ishizaki, T ^{[1
]}

机构：

[1] Kumamoto Univ, Grad Sch Clin Pharm, Dept Pharmacol & Therapeut, Kumamoto 8620973, Japan

来源：

PHARMACOLOGY & THERAPEUTICS | 2000年 / 86卷 / 01期

关键词：

pharmacogenetics; polymorphism; cytochromes P-450 (CYPs); cardiovascular drugs; cardiovascular diseases; pharmacodynamics;

D O I：

10.1016/S0163-7258(99)00066-2

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The variability in the individual response to drugs may be due either to interindividual variations in the pharmacokinetics of the drugs or to the heterogeneity of the mechanism(s) underlying the diseases, or both. In both cases, genetic heterogeneity is involved in the metabolism of cardiovascular drugs and pathogenesis of inherited cardiovascular disorders. Molecular genetic technologies can now provide sensitive and efficient genetic testing, not only to identify polymorphic drug metabolism genes, but also to identify disease-associated genes for diagnosis and risk stratification of many hereditary cardiovascular diseases. In this review, we discuss the polymorphic metabolism of cardiovascular drugs and the molecular genetics of cardiovascular diseases in relation to the genes determining the responsiveness to a given drug. (C) 2000 Elsevier Science Inc. All rights reserved.

引用

页码：1 / 28

页数：28

共 360 条

[71] PHARMACOGENETIC EXPLANATION FOR EXCESSIVE BETA-BLOCKADE FOLLOWING TIMOLOL EYE DROPS - POTENTIAL FOR ORAL-OPHTHALMIC DRUG-INTERACTION [J].

EDEKI, TI ;

HE, HB ;

WOOD, AJJ .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1995, 274 (20) :1611-1613

[72] DEFECTIVE N-OXIDATION OF SPARTEINE IN MAN - NEW PHARMACOGENETIC DEFECT [J].

EICHELBAUM, M ;

SPANNBRUCKER, N ;

STEINCKE, B ;

DENGLER, HJ .

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1979, 16 (03) :183-187

[73] T-type Ca2+ channels and pharmacological blockade:: Potential pathophysiological relevance [J].

Ertel, SI ;

Ertel, EA ;

Clozel, JP .

CARDIOVASCULAR DRUGS AND THERAPY, 1997, 11 (06) :723-739

[74]

EVANS DAP, 1989, PHARMACOL THERAPEUT, V42, P157

[75] A HUMAN VASCULAR DISORDER, SUPRAVALVULAR AORTIC-STENOSIS, MAPS TO CHROMOSOME-7 [J].

EWART, AK ;

MORRIS, CA ;

ENSING, GJ ;

LOKER, J ;

MOORE, C ;

LEPPERT, M ;

KEATING, M .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (08) :3226-3230

[76] DRUG-INDUCED TORSADE-DE-POINTES - INCIDENCE, MANAGEMENT AND PREVENTION [J].

FABER, TS ;

ZEHENDER, M ;

JUST, H .

DRUG SAFETY, 1994, 11 (06) :463-476

[77] Association of CYP3A4 genotype with treatment-related leukemia [J].

Felix, CA ;

Walker, AH ;

Lange, BJ ;

Williams, TM ;

Winick, NJ ;

Cheung, NKV ;

Lovett, BD ;

Nowell, PC ;

Blair, IA ;

Rebbeck, TR .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (22) :13176-13181

[78]

Ferguson RJ, 1998, J PHARMACOL EXP THER, V284, P356

[79] THE CYP 2A GENE SUBFAMILY - SPECIES-DIFFERENCES, REGULATION, CATALYTIC ACTIVITIES AND ROLE IN CHEMICAL CARCINOGENESIS [J].

FERNANDEZSALGUERO, P ;

GONZALEZ, FJ .

PHARMACOGENETICS, 1995, 5 :S123-S128

[80]

FERNANDEZSALGUERO P, 1995, AM J HUM GENET, V57, P651

← 3 4 5 6 7 8 9 10 11 12 →